Adopting Bispecific Agents for Multiple Myeloma into Practice

Videos — February 7, 2025

Featuring:

Laura R. Bobolts, PharmD, BCOP
Senior Vice President, Clinical Strategy and Growth
OncoHealth
Pompano Beach, FL
Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS
Director, Pharmacy Operations
Florida Cancer Specialists & Research Institute
Tampa, FL
Hakan Kaya, MD
Hematologic Oncologist and Senior Partner, Cancer Care Northwest
Director, Inland Northwest Myeloma/Lymphoma & Transplant Program
Clinical Professor, Elson S. Floyd College of Medicine, Washington State University
Clinical Professor of Medicine, University of Washington School of Medicine
Spokane, WA
Lisa Raff, PharmD, MSPharm, BCPS, BCOP
Vice President, Pharmacy Services
OneOncology
Nashville, TN
Yonatan Resnick, PharmD
Director, Pharmacy Clinical Services
New England Cancer Specialists
Scarborough, ME

In this third installment, Hakan Kaya, MD, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss considerations for adopting bispecific therapies into regular multiple myeloma clinical practice.

Related Articles